aTyr Pharma (STU:471A) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:471A aTyr Pharma Inc STU:471A
27 GF Score
Price €0.42
GF Value €0.38
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

aTyr Pharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

STU:471A vs IBO, BYSI, MCRB: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, aTyr Pharma's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

aTyr Pharma Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Margin of Safety % (DCF Dividends Based) falls into.


STU:471A
27GF Score
aTyr Pharma Inc STU:471A
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is aTyr Pharma (STU:471A) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of €0.42 is trading 9.5% above its estimated GF Value™ of €0.38. GuruFocus considers aTyr Pharma to be Fairly Valued.

Key valuation signals for STU:471A:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €0.38 vs. price of €0.42 (9.5% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the STU:471A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges ATYR:USA
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
27GF Score

Get the complete analysis for STU:471A

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price
€0.38
GF Value